Topiramate · Regulatory approval

FDA approval: Topiramate

U.S. Food and Drug Administration · July 22, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved an Abbreviated New Drug Application (ANDA) for generic extended-release topiramate capsules in four strengths (25 mg, 50 mg, 100 mg, 200 mg) from Biocon Pharma, effective 22 July 2026. This is a regulatory manufacturing and bioequivalence action and does not report clinical trial results or comparative efficacy.

What was studied

Regulatory approval. Intervention: Topiramate extended-release capsules, 25 mg, 50 mg, 100 mg, and 200 mg oral formulations.

Key findings

ANDA220943 approved for topiramate extended-release capsules in strengths of 25 mg, 50 mg, 100 mg, and 200 mg Sponsor: Biocon Pharma; approval date 2026-07-22

Safety

This record does not contain clinical trial results, efficacy data, or safety findings. Sponsor: Biocon Pharma; approval date 2026-07-22

Who this may help

This approval enables generic supply of extended-release topiramate and may improve access and reduce cost. Clinicians should note that the approval itself does not report new efficacy or safety data; the clinical profile of topiramate remains as previously established.

Plain-language summary

FDA approval of a generic extended-release topiramate formulation; regulatory action that expands market access but does not itself report clinical efficacy or comparative trial data.

Study design

As stated by the source record.

InterventionTopiramate extended-release capsules, 25 mg, 50 mg, 100 mg, and 200 mg oral formulations

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-22

Product strengths25 mg, 50 mg, 100 mg, 200 mg

Clinical bottom line

Caveats

This record does not contain clinical trial results, efficacy data, or safety findings.
ANDA approval is based on bioequivalence to a reference listed drug, not de novo clinical evidence.
No patient population, sample size, or comparative outcome data are reported.
The record does not specify which reference drug was used for bioequivalence comparison.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no clinical study design reported.

Directness

insufficient

Approval record does not report clinical outcomes or trial comparisons.

Consistency

insufficient

No comparative data or replication reported in this record.

Risk of bias

insufficient

Not applicable to a regulatory approval action.

Sample adequacy

insufficient

No patient sample or trial data included in this record.

Source abstract

Drugs@FDA record for application ANDA220943. This is a regulatory action record, not a clinical study. Brand name: TOPIRAMATE. Active ingredient: TOPIRAMATE. Sponsor: BIOCON PHARMA. Submission type: ORIG (original application). Approval status date: 2026-07-22. Products: TOPIRAMATE, CAPSULE, EXTENDED RELEASE, ORAL, TOPIRAMATE 200MG; TOPIRAMATE, CAPSULE, EXTENDED RELEASE, ORAL, TOPIRAMATE 50MG; TOPIRAMATE, CAPSULE, EXTENDED RELEASE, ORAL, TOPIRAMATE 100MG; TOPIRAMATE, CAPSULE, EXTENDED RELEASE, ORAL, TOPIRAMATE 25MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Biocon PharmaTopiramate